1
|
Furuya T, Lin J, Afanaseva A, Molz L, Lagu B, Ma B. Discovery of Potent Allosteric DRP1 Inhibitors by Disrupting Protein-Protein Interaction with MiD49. ACS Med Chem Lett 2023; 14:1095-1099. [PMID: 37583827 PMCID: PMC10424310 DOI: 10.1021/acsmedchemlett.3c00223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Accepted: 07/20/2023] [Indexed: 08/17/2023] Open
Abstract
Mitochondrial dysfunction has been attributed to many disease indications, including metabolic, cardiovascular, neoplastic, and neurodegenerative diseases. Dynamin related protein 1 (DRP1) is crucial in regulating mitochondrial fission and maintaining mitochondrial homeostasis. MiD49 is a dynamic peripheral protein receptor on the surface of the mitochondrial membrane that recruits DRP1 protein to induce mitochondrial binary fission. By targeting the protein-protein interaction of DRP1/MiD49, we have discovered a novel and potent allosteric DRP1 inhibitor that inhibits mitochondria fragmentation in vitro. X-ray cocrystal structure revealed that it locked the closed DRP1 conformation by induced dimerization.
Collapse
Affiliation(s)
| | | | | | | | | | - Bin Ma
- Mitobridge, Inc., an Astellas Company, Cambridge, Massachusetts 02138, United States
| |
Collapse
|
2
|
Lagu B, Wu X, Kulkarni S, Paul R, Becherer JD, Olson L, Ravani S, Chatzianastasiou A, Papapetropoulos A, Andrzejewski S. Orally Bioavailable Enzymatic Inhibitor of CD38, MK-0159, Protects against Ischemia/Reperfusion Injury in the Murine Heart. J Med Chem 2022; 65:9418-9446. [PMID: 35762533 DOI: 10.1021/acs.jmedchem.2c00688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
CD38 is one of the major nicotinamide adenine dinucleotide (NAD+)- and nicotinamide adenine dinucleotide phosphate (NADP+)-consuming enzymes in mammals. NAD+, NADP+, and their reduced counterparts are essential coenzymes for numerous enzymatic reactions, including the maintenance of cellular and mitochondrial redox balance. CD38 expression is upregulated in age-associated inflammation as well as numerous metabolic diseases, resulting in cellular and mitochondrial dysfunction. Recent literature studies demonstrate that CD38 is activated upon ischemia/reperfusion (I/R), leading to a depletion of NADP+, which results in endothelial damage and myocardial infarction in the heart. Despite increasing evidence of CD38 involvement in various disease states, relatively few CD38 enzymatic inhibitors have been reported to date. Herein, we describe a CD38 enzymatic inhibitor (MK-0159, IC50 = 3 nM against murine CD38) that inhibits CD38 in in vitro assay. Mice treated with MK-0159 show strong protection from myocardial damage upon cardiac I/R injury compared to those treated with NAD+ precursors (nicotinamide riboside) or the known CD38 inhibitor, 78c.
Collapse
Affiliation(s)
- Bharat Lagu
- Mitobridge (An Astellas Company), Cambridge, Massachusetts 02138, United States
| | - Xinyuan Wu
- Mitobridge (An Astellas Company), Cambridge, Massachusetts 02138, United States
| | - Santosh Kulkarni
- Syngene International Limited, Bangalore, Karnataka 560099, India
| | - Rakesh Paul
- Syngene International Limited, Bangalore, Karnataka 560099, India
| | - J David Becherer
- Mitobridge (An Astellas Company), Cambridge, Massachusetts 02138, United States
| | - Lyndsay Olson
- Mitobridge (An Astellas Company), Cambridge, Massachusetts 02138, United States
| | - Stella Ravani
- Clinical, Experimental Surgery and Translational Research Center, Biomedical Research Foundation of the Academy of Athens, Athens 11527, Greece
| | - Athanasia Chatzianastasiou
- Clinical, Experimental Surgery and Translational Research Center, Biomedical Research Foundation of the Academy of Athens, Athens 11527, Greece.,Laboratory of Pharmacology, Department of Pharmacy, National and Kapodistrian University of Athens, Athens 15771, Greece
| | - Andreas Papapetropoulos
- Clinical, Experimental Surgery and Translational Research Center, Biomedical Research Foundation of the Academy of Athens, Athens 11527, Greece.,Laboratory of Pharmacology, Department of Pharmacy, National and Kapodistrian University of Athens, Athens 15771, Greece
| | - Sylvia Andrzejewski
- Mitobridge (An Astellas Company), Cambridge, Massachusetts 02138, United States
| |
Collapse
|
3
|
Lagu B, Senaiar RS, Kluge AF, Mallesh B, Ramakrishna M, Bhat R, Patane MA. Addressing hERG activity while maintaining favorable potency, selectivity and pharmacokinetic properties of PPARδ modulators. Bioorg Med Chem Lett 2020; 30:126928. [PMID: 31889664 DOI: 10.1016/j.bmcl.2019.126928] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Revised: 12/16/2019] [Accepted: 12/20/2019] [Indexed: 01/08/2023]
Abstract
One of the most commonly used strategies to reduce hERG (human ether-a-go-go) activity in the drug candidates is introduction of a carboxylic acid group. During the optimization of PPARδ modulators, some of the compounds containing a carboxylic acid were found to inhibit the hERG channel in a patch clamp assay. By modifying the basicity of the imidazole core, potent and selective PPARδ modulators that do not inhibit hERG channel were identified. Some of the modulators have excellent pharmacokinetic profiles in mice.
Collapse
Affiliation(s)
- Bharat Lagu
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, MA 02138, USA.
| | | | - Arthur F Kluge
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, MA 02138, USA
| | - B Mallesh
- Aurigene Discovery Technologies, Ltd., Bengaluru, India
| | - M Ramakrishna
- Aurigene Discovery Technologies, Ltd., Bengaluru, India
| | | | - Michael A Patane
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, MA 02138, USA
| |
Collapse
|
4
|
Troxler T, Feuerbach D, Zhang X, Yang CR, Lagu B, Perrone M, Wang T, Briner K, Bock MG, Auberson YP. Front Cover: The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders (ChemMedChem 13/2019). ChemMedChem 2019. [DOI: 10.1002/cmdc.201900365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Thomas Troxler
- Novartis Institutes for BioMedical ResearchNovartis Pharma AG Klybeckstrasse 141 4057 Basel Switzerland
| | - Dominik Feuerbach
- Novartis Institutes for BioMedical ResearchNovartis Pharma AG Klybeckstrasse 141 4057 Basel Switzerland
| | - Xuechun Zhang
- ChemPartner 998 Halei Road, Zhangjiang Hi-Tech Park Pudong New Area Shanghai 201203 China
| | - Charles R. Yang
- ShangPharma Innovation Inc. 280 Utah Avenue South San Francisco CA 94080 USA
| | - Bharat Lagu
- Novartis Institutes for BioMedical ResearchNovartis Pharma AG 250 Massachusetts Avenue Cambridge MA 02139 USA
| | - Mark Perrone
- Novartis Institutes for BioMedical ResearchNovartis Pharma AG 250 Massachusetts Avenue Cambridge MA 02139 USA
| | - Tie‐Lin Wang
- ChemPartner 998 Halei Road, Zhangjiang Hi-Tech Park Pudong New Area Shanghai 201203 China
| | - Karin Briner
- Novartis Institutes for BioMedical ResearchNovartis Pharma AG 250 Massachusetts Avenue Cambridge MA 02139 USA
| | - Mark G. Bock
- Novartis Institutes for BioMedical ResearchNovartis Pharma AG 250 Massachusetts Avenue Cambridge MA 02139 USA
| | - Yves P. Auberson
- Novartis Institutes for BioMedical ResearchNovartis Pharma AG Klybeckstrasse 141 4057 Basel Switzerland
| |
Collapse
|
5
|
Lagu B, Kluge AF, Tozzo E, Fredenburg R, Bell EL, Goddeeris MM, Dwyer P, Basinski A, Senaiar RS, Jaleel M, Tiwari NK, Panigrahi SK, Krishnamurthy NR, Takahashi T, Patane MA. Correction to "Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)". ACS Med Chem Lett 2019; 10:1013. [PMID: 31223463 DOI: 10.1021/acsmedchemlett.9b00160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
[This corrects the article DOI: 10.1021/acsmedchemlett.8b00287.].
Collapse
|
6
|
Troxler T, Feuerbach D, Zhang X, Yang CR, Lagu B, Perrone M, Wang TL, Briner K, Bock MG, Auberson YP. The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders. ChemMedChem 2019; 14:1238-1247. [PMID: 30957954 DOI: 10.1002/cmdc.201900176] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Indexed: 12/12/2022]
Abstract
Histamine H3 receptor (H3R) inverse agonists that have been in clinical trials for the treatment of excessive sleep disorders, have been plagued with insomnia as a mechanism-based side effect. We focused on the identification of compounds that achieve high receptor occupancy within a short time, followed by rapid disengagement from the receptor, a target profile that could provide therapeutic benefits without the undesired side effect of insomnia. This article describes the optimization work that led to the discovery of 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate (18 b, LML134).
Collapse
Affiliation(s)
- Thomas Troxler
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, Klybeckstrasse 141, 4057, Basel, Switzerland
| | - Dominik Feuerbach
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, Klybeckstrasse 141, 4057, Basel, Switzerland
| | - Xuechun Zhang
- ChemPartner, 998 Halei Road, Zhangjiang Hi-Tech Park Pudong New Area, Shanghai, 201203, China
| | - Charles R Yang
- ShangPharma Innovation Inc., 280 Utah Avenue, South San Francisco, CA, 94080, USA
| | - Bharat Lagu
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Mark Perrone
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Tie-Lin Wang
- ChemPartner, 998 Halei Road, Zhangjiang Hi-Tech Park Pudong New Area, Shanghai, 201203, China
| | - Karin Briner
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Mark G Bock
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Yves P Auberson
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, Klybeckstrasse 141, 4057, Basel, Switzerland
| |
Collapse
|
7
|
Lagu B, Kluge AF, Tozzo E, Fredenburg R, Bell EL, Goddeeris MM, Dwyer P, Basinski A, Senaiar RS, Jaleel M, Tiwari NK, Panigrahi SK, Krishnamurthy NR, Takahashi T, Patane MA. Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD). ACS Med Chem Lett 2018; 9:935-940. [PMID: 30258544 DOI: 10.1021/acsmedchemlett.8b00287] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2018] [Accepted: 07/31/2018] [Indexed: 01/14/2023] Open
Abstract
The X-ray structure of the previously reported PPARδ modulator 1 bound to the ligand binding domain (LBD) revealed that the amide moiety in 1 exists in the thermodynamically disfavored cis-amide orientation. Isosteric replacement of the cis-amide with five-membered heterocycles led to the identification of imidazole 17 (MA-0204), a potent, selective PPARδ modulator with good pharmacokinetic properties. MA-0204 was tested in vivo in mice and in vitro in patient-derived muscle myoblasts (from Duchenne Muscular Dystrophy (DMD) patients); 17 altered the expression of PPARδ target genes and improved fatty acid oxidation, which supports the therapeutic hypothesis for the study of MA-0204 in DMD patients.
Collapse
Affiliation(s)
- Bharat Lagu
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States
| | - Arthur F. Kluge
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States
| | - Effie Tozzo
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States
| | - Ross Fredenburg
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States
| | - Eric L. Bell
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States
| | - Matthew M. Goddeeris
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States
| | - Peter Dwyer
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States
| | - Andrew Basinski
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States
| | - Ramesh S. Senaiar
- Aurigene Discovery Technologies, Ltd., Bengaluru and Hyderabad, India
| | - Mahaboobi Jaleel
- Aurigene Discovery Technologies, Ltd., Bengaluru and Hyderabad, India
| | | | | | | | | | - Michael A. Patane
- Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States
| |
Collapse
|
8
|
Lagu B, Kluge AF, Fredenburg RA, Tozzo E, Senaiar RS, Jaleel M, Panigrahi SK, Tiwari NK, Krishnamurthy NR, Takahashi T, Patane MA. Novel highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulators with pharmacokinetic properties suitable for once-daily oral dosing. Bioorg Med Chem Lett 2017; 27:5230-5234. [PMID: 29103972 DOI: 10.1016/j.bmcl.2017.10.037] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 09/26/2017] [Accepted: 10/18/2017] [Indexed: 11/16/2022]
Abstract
Optimization of benzamide PPARδ modulator 1 led to (E)-6-(2-((4-(furan-2-yl)-N-methylbenzamido)methyl)phenoxy)-4-methylhex-4-enoic acid (18), a potent selective PPARδ modulator with significantly improved exposure in multiple species following oral administration.
Collapse
Affiliation(s)
- Bharat Lagu
- Mitobridge, Inc., 1030 Massachusetts Ave., Cambridge, MA 02138, United States.
| | - Arthur F Kluge
- Mitobridge, Inc., 1030 Massachusetts Ave., Cambridge, MA 02138, United States
| | - Ross A Fredenburg
- Mitobridge, Inc., 1030 Massachusetts Ave., Cambridge, MA 02138, United States
| | - Effie Tozzo
- Mitobridge, Inc., 1030 Massachusetts Ave., Cambridge, MA 02138, United States
| | - Ramesh S Senaiar
- Aurigene Discovery Technologies, Ltd., Hyderabad and Bengaluru, India
| | - Mahaboobi Jaleel
- Aurigene Discovery Technologies, Ltd., Hyderabad and Bengaluru, India
| | - Sunil K Panigrahi
- Aurigene Discovery Technologies, Ltd., Hyderabad and Bengaluru, India
| | - Nirbhay K Tiwari
- Aurigene Discovery Technologies, Ltd., Hyderabad and Bengaluru, India
| | | | | | - Michael A Patane
- Mitobridge, Inc., 1030 Massachusetts Ave., Cambridge, MA 02138, United States
| |
Collapse
|
9
|
Auberson YP, Troxler T, Zhang X, Yang CR, Feuerbach D, Liu YC, Lagu B, Perrone M, Lei L, Shen X, Zhang D, Wang C, Wang TL, Briner K, Bock MG. From ergolines to indoles: improved inhibitors of the human H3 receptor for the treatment of narcolepsy. ChemMedChem 2014; 10:266-75. [PMID: 25394333 DOI: 10.1002/cmdc.201402418] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2014] [Indexed: 11/07/2022]
Abstract
Ergolines were recently identified as a novel class of H3 receptor (H3R) inverse agonists. Although their optimization led to drug candidates with encouraging properties for the treatment of narcolepsy, brain penetration remained low. To overcome this issue, ergoline 1 ((6aR,9R,10aR)-4-(2-(dimethylamino)ethyl)-N-phenyl-9-(pyrrolidine-1-carbonyl)-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-7(4H)-carboxamide)) was transformed into a series of indole derivatives with high H3R affinity. These new molecules were profiled by simultaneous determination of their brain receptor occupancy (RO) levels and pharmacodynamic (PD) effects in mice. These efforts culminated in the discovery of 15 m ((R)-1-isopropyl-5-(1-(2-(2-methylpyrrolidin-1-yl)ethyl)-1H-indol-4-yl)pyridin-2(1H)-one), which has an ideal profile showing a strong correlation of PD effects with RO, and no measurable safety liabilities. Its desirably short duration of action was confirmed by electroencephalography (EEG) measurements in rats.
Collapse
Affiliation(s)
- Yves P Auberson
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4058 Basel (Switzerland).
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Ullrich T, Sasmal S, Boorgu V, Pasagadi S, Cheera S, Rajagopalan S, Bhumireddy A, Shashikumar D, Chelur S, Belliappa C, Pandit C, Krishnamurthy N, Mukherjee S, Ramanathan A, Ghadiyaram C, Ramachandra M, Santos PG, Lagu B, Bock MG, Perrone MH, Weiler S, Keller H. 3-Alkoxy-pyrrolo[1,2-b]pyrazolines as Selective Androgen Receptor Modulators with Ideal Physicochemical Properties for Transdermal Administration. J Med Chem 2014; 57:7396-411. [DOI: 10.1021/jm5009049] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | - Sanjita Sasmal
- Aurigene Discovery
Technologies Ltd, Bollaram Road, Miyapur, Hyderabad 500 049, India
| | - Venkatesham Boorgu
- Aurigene Discovery
Technologies Ltd, Bollaram Road, Miyapur, Hyderabad 500 049, India
| | - Srinivasu Pasagadi
- Aurigene Discovery
Technologies Ltd, Bollaram Road, Miyapur, Hyderabad 500 049, India
| | - Srisailam Cheera
- Aurigene Discovery
Technologies Ltd, Bollaram Road, Miyapur, Hyderabad 500 049, India
| | - Sujatha Rajagopalan
- Aurigene Discovery
Technologies Ltd, 39-40, KIADB Industrial
Area, Electronic City Phase II, Hosur Road, Bangalore 560 100, India
| | - Archana Bhumireddy
- Aurigene Discovery
Technologies Ltd, 39-40, KIADB Industrial
Area, Electronic City Phase II, Hosur Road, Bangalore 560 100, India
| | - Dhanya Shashikumar
- Aurigene Discovery
Technologies Ltd, Bollaram Road, Miyapur, Hyderabad 500 049, India
| | - Shekar Chelur
- Aurigene Discovery
Technologies Ltd, 39-40, KIADB Industrial
Area, Electronic City Phase II, Hosur Road, Bangalore 560 100, India
| | - Charamanna Belliappa
- Aurigene Discovery
Technologies Ltd, 39-40, KIADB Industrial
Area, Electronic City Phase II, Hosur Road, Bangalore 560 100, India
| | - Chetan Pandit
- Aurigene Discovery
Technologies Ltd, 39-40, KIADB Industrial
Area, Electronic City Phase II, Hosur Road, Bangalore 560 100, India
| | - Narasimharao Krishnamurthy
- Aurigene Discovery
Technologies Ltd, 39-40, KIADB Industrial
Area, Electronic City Phase II, Hosur Road, Bangalore 560 100, India
| | - Subhendu Mukherjee
- Aurigene Discovery
Technologies Ltd, 39-40, KIADB Industrial
Area, Electronic City Phase II, Hosur Road, Bangalore 560 100, India
| | - Anuradha Ramanathan
- Aurigene Discovery
Technologies Ltd, 39-40, KIADB Industrial
Area, Electronic City Phase II, Hosur Road, Bangalore 560 100, India
| | - Chakshusmathi Ghadiyaram
- Aurigene Discovery
Technologies Ltd, 39-40, KIADB Industrial
Area, Electronic City Phase II, Hosur Road, Bangalore 560 100, India
| | - Murali Ramachandra
- Aurigene Discovery
Technologies Ltd, 39-40, KIADB Industrial
Area, Electronic City Phase II, Hosur Road, Bangalore 560 100, India
| | - Paulo G. Santos
- Technical
Research
and Development, Novartis Pharma AG, CH-4002 Basel, Switzerland
| | - Bharat Lagu
- Global
Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge Massachusetts 02139, United States
| | - Mark G. Bock
- Global
Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge Massachusetts 02139, United States
| | - Mark H. Perrone
- Global
Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge Massachusetts 02139, United States
| | | | | |
Collapse
|
11
|
Auberson YP, Troxler T, Zhang X, Yang CR, Fendt M, Feuerbach D, Liu YC, Lagu B, Lerchner A, Perrone M, Lei L, Zhang C, Wang C, Wang TL, Bock MG. Cover Picture: Ergoline-Derived Inverse Agonists of the Human H3 Receptor for the Treatment of Narcolepsy (ChemMedChem 8/2014). ChemMedChem 2014. [DOI: 10.1002/cmdc.201490028] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
12
|
Auberson YP, Troxler T, Zhang X, Yang CR, Fendt M, Feuerbach D, Liu YC, Lagu B, Lerchner A, Perrone M, Lei L, Zhang C, Wang C, Wang TL, Bock MG. Ergoline-Derived Inverse Agonists of the Human H3 Receptor for the Treatment of Narcolepsy. ChemMedChem 2014; 9:1683-96. [DOI: 10.1002/cmdc.201402055] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Indexed: 02/03/2023]
|
13
|
Shultz MD, Cheung AK, Kirby CA, Firestone B, Fan J, Chen CHT, Chen Z, Chin DN, DiPietro L, Fazal A, Feng Y, Fortin PD, Gould T, Lagu B, Lei H, Lenoir F, Majumdar D, Ochala E, Palermo MG, Pham L, Pu M, Smith T, Stams T, Tomlinson RC, Touré BB, Visser M, Wang RM, Waters NJ, Shao W. Identification of NVP-TNKS656: The Use of Structure–Efficiency Relationships To Generate a Highly Potent, Selective, and Orally Active Tankyrase Inhibitor. J Med Chem 2013; 56:6495-511. [DOI: 10.1021/jm400807n] [Citation(s) in RCA: 98] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Michael D. Shultz
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Atwood K. Cheung
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Christina A. Kirby
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Brant Firestone
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Jianmei Fan
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Christine Hiu-Tung Chen
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Zhouliang Chen
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Donovan N. Chin
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Lucian DiPietro
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Aleem Fazal
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Yun Feng
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Pascal D. Fortin
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Ty Gould
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Bharat Lagu
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Huangshu Lei
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Francois Lenoir
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Dyuti Majumdar
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Etienne Ochala
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - M. G. Palermo
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Ly Pham
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Minying Pu
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Troy Smith
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Travis Stams
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Ronald C. Tomlinson
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - B. Barry Touré
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Michael Visser
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Run Ming Wang
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Nigel J. Waters
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| | - Wenlin Shao
- Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts
02139, United States
| |
Collapse
|
14
|
Peukert S, He F, Dai M, Zhang R, Sun Y, Miller-Moslin K, McEwan M, Lagu B, Wang K, Yusuff N, Bourret A, Ramamurthy A, Maniara W, Amaral A, Vattay A, Wang A, Guo R, Yuan J, Green J, Williams J, Buonamici S, Kelleher JF, Dorsch M. Cover Picture: Discovery of NVP-LEQ506, a Second-Generation Inhibitor of Smoothened (ChemMedChem 8/2013). ChemMedChem 2013. [DOI: 10.1002/cmdc.201390030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
15
|
Peukert S, He F, Dai M, Zhang R, Sun Y, Miller-Moslin K, McEwan M, Lagu B, Wang K, Yusuff N, Bourret A, Ramamurthy A, Maniara W, Amaral A, Vattay A, Wang A, Guo R, Yuan J, Green J, Williams J, Buonamici S, Kelleher JF, Dorsch M. Discovery of NVP-LEQ506, a Second-Generation Inhibitor of Smoothened. ChemMedChem 2013; 8:1261-5. [DOI: 10.1002/cmdc.201300217] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2013] [Indexed: 01/17/2023]
|
16
|
Cho YS, Angove H, Brain C, Chen CHT, Cheng H, Cheng R, Chopra R, Chung K, Congreve M, Dagostin C, Davis DJ, Feltell R, Giraldes J, Hiscock SD, Kim S, Kovats S, Lagu B, Lewry K, Loo A, Lu Y, Luzzio M, Maniara W, McMenamin R, Mortenson PN, Benning R, O'Reilly M, Rees DC, Shen J, Smith T, Wang Y, Williams G, Woolford AJA, Wrona W, Xu M, Yang F, Howard S. Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors. ACS Med Chem Lett 2012; 3:445-9. [PMID: 24900493 DOI: 10.1021/ml200241a] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2011] [Accepted: 04/16/2012] [Indexed: 11/28/2022] Open
Abstract
Herein, we describe the discovery of potent and highly selective inhibitors of both CDK4 and CDK6 via structure-guided optimization of a fragment-based screening hit. CDK6 X-ray crystallography and pharmacokinetic data steered efforts in identifying compound 6, which showed >1000-fold selectivity for CDK4 over CDKs 1 and 2 in an enzymatic assay. Furthermore, 6 demonstrated in vivo inhibition of pRb-phosphorylation and oral efficacy in a Jeko-1 mouse xenograft model.
Collapse
Affiliation(s)
- Young Shin Cho
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Hayley Angove
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Christopher Brain
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Christine Hiu-Tung Chen
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Hong Cheng
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Robert Cheng
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Rajiv Chopra
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Kristy Chung
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Miles Congreve
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Claudio Dagostin
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Deborah J. Davis
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Ruth Feltell
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - John Giraldes
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Steven D. Hiscock
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Sunkyu Kim
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Steven Kovats
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Bharat Lagu
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Kim Lewry
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Alice Loo
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Yipin Lu
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Michael Luzzio
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Wiesia Maniara
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Rachel McMenamin
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Paul N. Mortenson
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Rajdeep Benning
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Marc O'Reilly
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - David C. Rees
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Junqing Shen
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Troy Smith
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Yaping Wang
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Glyn Williams
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Alison J.-A. Woolford
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| | - Wojciech Wrona
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Mei Xu
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Fan Yang
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139, United States
| | - Steven Howard
- Astex Pharmaceuticals Inc., 436 Cambridge Science Park, Milton Road, Cambridge,
CB4 0QA, United Kingdom
| |
Collapse
|
17
|
Genovino J, Lagu B, Wang Y, Touré BB. Synthesis of sterically hindered enamides via a Ti-mediated condensation of amides with aldehydes and ketones. Chem Commun (Camb) 2012; 48:6735-7. [PMID: 22643736 DOI: 10.1039/c2cc32538a] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The first TiCl(4)-mediated condensation of secondary amides with aldehydes and ketones has been achieved. The reaction proceeds at room temperature and is complete within 5 h in most cases. The optimized procedure used 5 equiv of an amine base hinting that the in situ activation of both the amide and the Lewis acid is required. The reaction affords polysubstituted (E)-enamides.
Collapse
Affiliation(s)
- Julien Genovino
- Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA
| | | | | | | |
Collapse
|
18
|
Peukert S, Nunez J, He F, Dai M, Yusuff N, DiPesa A, Miller-Moslin K, Karki R, Lagu B, Harwell C, Zhang Y, Bauer D, Kelleher JF, Egan W. A method for estimating the risk of drug-induced phototoxicity and its application to smoothened inhibitors. Med Chem Commun 2011. [DOI: 10.1039/c1md00144b] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
19
|
Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV. β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 1. Design, synthesis, and lead identification. Bioorg Med Chem Lett 2008; 18:1135-9. [DOI: 10.1016/j.bmcl.2007.11.119] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2007] [Revised: 11/28/2007] [Accepted: 11/30/2007] [Indexed: 01/17/2023]
|
20
|
Yang SM, Lagu B, Wilson LJ. Mild and efficient Lewis acid-promoted detritylation in the synthesis of N-hydroxy amides: a concise synthesis of (-)-Cobactin T. J Org Chem 2007; 72:8123-6. [PMID: 17880142 DOI: 10.1021/jo701411d] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
An efficient, high-yielding Lewis acid promoted deprotection of O-trityl hydroxylamine derivatives is described. A range of acid-labile protecting groups, such as N-Boc and O-TBS, were tolerated under these mild conditions. The present method is applicable to the synthesis of a broad range of hydroxylamine derivatives, including N-hydroxy amides (hydroxamic acids), N-hydroxy sulfonamides, and N-hydroxy ureas, which often exhibit significant biological activities. An application of this methodology for a concise synthesis of (-)-Cobactin T (18) is also demonstrated.
Collapse
Affiliation(s)
- Shyh-Ming Yang
- Johnson & Johnson Pharmaceutical Research and Development, L.L.C. 8 Clarke Drive, Cranbury, New Jersey 08512, USA.
| | | | | |
Collapse
|
21
|
Lagu B, Pio B, Lebedev R, Yang M, Pelton PD. RXR–LXR heterodimer modulators for the potential treatment of dyslipidemia. Bioorg Med Chem Lett 2007; 17:3497-503. [PMID: 17485209 DOI: 10.1016/j.bmcl.2007.01.047] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2006] [Revised: 01/09/2007] [Accepted: 01/11/2007] [Indexed: 10/23/2022]
Abstract
A number of RXR agonists were synthesized and screened in functional assays. The synthesis and the structure-activity relationship (SAR) within the series of compounds will be presented. Some in vivo data in rodent models for dyslipidemia and diabetes will also be presented.
Collapse
Affiliation(s)
- Bharat Lagu
- Johnson and Johnson Pharmaceutical Research and Development, Cranbury, NJ 08869, USA.
| | | | | | | | | |
Collapse
|
22
|
Lagu B, Lebedev R, Pio B, Yang M, Pelton PD. Dihydro-[1H]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia. Bioorg Med Chem Lett 2007; 17:3491-6. [PMID: 17490875 DOI: 10.1016/j.bmcl.2007.01.049] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2006] [Revised: 01/09/2007] [Accepted: 01/11/2007] [Indexed: 11/29/2022]
Abstract
A number of RXR modulators with novel structural features were synthesized and screened in the functional assays. The synthesis and the structure-activity relationship within the series of compounds will be presented. Some in vivo data generated in the models for dyslipidemia and diabetes will also be presented.
Collapse
Affiliation(s)
- Bharat Lagu
- Johnson and Johnson Pharmaceutical Research and Development, Cranbury, NJ 08512, USA.
| | | | | | | | | |
Collapse
|
23
|
Lagu B, Gerchak C, Pan M, Hou C, Singer M, Malaviya R, Matheis M, Olini G, Cavender D, Wachter M. Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma. Bioorg Med Chem Lett 2007; 17:4382-6. [PMID: 17587570 DOI: 10.1016/j.bmcl.2007.01.115] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2006] [Revised: 01/24/2007] [Accepted: 01/25/2007] [Indexed: 10/23/2022]
Abstract
A number of compounds bearing a quaternary ammonium moiety were found to be antagonists with nanomolar binding affinity for the chemokine receptor-2. The structure-activity relationships in the series are described herein along with some detailed characterization of the interesting compounds.
Collapse
Affiliation(s)
- Bharat Lagu
- Johnson & Johnson Pharmaceutical Research and Development, Cranbury, NJ 08512, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Konkel MJ, Lagu B, Boteju LW, Jimenez H, Noble S, Walker MW, Chandrasena G, Blackburn TP, Nikam SS, Wright JL, Kornberg BE, Gregory T, Pugsley TA, Akunne H, Zoski K, Wise LD. 3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists. J Med Chem 2006; 49:3757-8. [PMID: 16789730 DOI: 10.1021/jm060001n] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A series of 3-imino-2-indolones are the first published, high-affinity antagonists of the galanin GAL3 receptor. One example, 1,3-dihydro-1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-2H-indol-2-one (9), was shown to have high affinity for the human GAL3 receptor (Ki=17 nM) and to be highly selective for GAL3 over a broad panel of targets, including GAL1 and GAL2. Compound 9 was also shown to be an antagonist in a human GAL3 receptor functional assay (Kb=29 nM).
Collapse
Affiliation(s)
- Michael J Konkel
- Lundbeck Research USA, Inc., 215 College Road, Paramus, New Jersey 07652, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP, Branchek TA, Gerald C, Vaysse PJ, Forray C. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 2002; 8:825-30. [PMID: 12118247 DOI: 10.1038/nm741] [Citation(s) in RCA: 229] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Melanin concentrating hormone (MCH) is an orexigenic hypothalamic neuropeptide, which plays an important role in the complex regulation of energy balance and body weight. Here we show that SNAP-7941, a selective, high-affinity MCH1 receptor (MCH1-R) antagonist, inhibited food intake stimulated by central administration of MCH, reduced consumption of palatable food, and, after chronic administration to rats with diet-induced obesity, resulted in a marked, sustained decrease in body weight. In addition, after mapping the binding sites for [(3)H]SNAP-7941 in rat brain, we evaluated its effects in a series of behavioral models. SNAP-7941 produced effects similar to clinically used antidepressants and anxiolytics in three animal models of depression/anxiety: the rat forced-swim test, rat social interaction and guinea pig maternal-separation vocalization tests. Given these observations, an MCH1-R antagonist may be useful not only in the management of obesity but also as a treatment for depression and/or anxiety.
Collapse
Affiliation(s)
- Beth Borowsky
- Synaptic Pharmaceutical Corporation, Paramus, New Jersey, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Dieter RK, Deo N, Lagu B, Dieter JW. Stereo- and regioselective synthesis of chiral diamines and triamines from pseudoephedrine and ephedrine. J Org Chem 2002. [DOI: 10.1021/jo00032a013] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
|
28
|
|
29
|
|
30
|
Lagu B, Wetzel JM, Forray C, Patane MA, Bock MG. Determination of the relative and absolute stereochemistry of a potent and alpha1A-selective adrenoceptor antagonist. Bioorg Med Chem Lett 2000; 10:2705-7. [PMID: 11133073 DOI: 10.1016/s0960-894x(00)00524-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The binding affinities and selectivities of antagonists 1-4 for the alpha1A-adrenoceptor are dependent on the stereochemical orientation of the groups at the C-4 and C-5 positions of the oxazolidinone ring. The unambiguous assignment of the relative and absolute configurations of the diastereomers of SNAP 7915 (1) is reported.
Collapse
Affiliation(s)
- B Lagu
- Department of Chemistry, Synaptic Pharmaceutical Corporation, Paramus, NJ 07652, USA.
| | | | | | | | | |
Collapse
|
31
|
Chang RS, Chen TB, O'Malley SS, Pettibone DJ, DiSalvo J, Francis B, Bock MG, Freidinger R, Nagarathnam D, Miao SW, Shen Q, Lagu B, Murali Dhar TG, Tyagarajan S, Marzabadi MR, Wong WC, Gluchowski C, Forray C. In vitro studies on L-771,688 (SNAP 6383), a new potent and selective alpha1A-adrenoceptor antagonist. Eur J Pharmacol 2000; 409:301-12. [PMID: 11108825 DOI: 10.1016/s0014-2999(00)00854-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
L-771,688 (SNAP 6383, methyl(4S)-4-(3, 4-difluorophenyl)-6-[(methyloxy)methyl]-2-oxo-3-[(¿3-[4-(2-pyridin yl)-1-piperidinyl]propyl¿amino)carbonyl]-1,2,3, 4-tetrahydro-5-pyrimidine carboxylate) had high affinity (Ki less than or = 1 nM) for [3H]prazosin binding to cloned human, rat and dog alpha1A-adrenoceptors and high selectivity (>500-fold) over alpha1B and alpha1D-adrenoceptors. [3H]Prazosin / (+/-)-beta-[125I]-4-hydroxy-phenyl)-ethyl-aminomethylteralone ([125I]HEAT) binding studies in human and animal tissues known to contain alpha1A and non-alpha1A-adrenoceptors further demonstrated the potency and alpha1A-subtype selectivity of L-771,688. [3H]L-771,688 binding studies at the cloned human alpha1A-adrenoceptors and in rat tissues indicated that specific [3H]L-771,688 binding was saturable and of high affinity (Kd=43-90 pM) and represented binding to the pharmacologically relevant alpha1A-adrenoceptors. L-771,688 antagonized norepinephrine-induced inositol-phosphate responses in cloned human alpha1A-adrenoceptors, as well as phenylephrine or A-61603 (N-[5-4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7, 8-terahydro-naphthlen-1-yl] methanesulfonamide hydrobromide) induced contraction in isolated rat, dog and human prostate, human and monkey bladder neck and rat caudal artery with apparent Kb values of 0.02-0.28 nM. In contrast, the contraction of rat aorta induced by norepinephrine was resistant to L-771,688. These data indicate that L-771,688 is a highly selective alpha1A-adrenoceptor antagonist.
Collapse
Affiliation(s)
- R S Chang
- Department of Pharmacology, Merck Research Laboratories, WP 46-300, P.O. Box 4, West Point, PA 19486-0004, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Lagu B, Tian D, Jeon Y, Li C, Wetzel JM, Nagarathnam D, Shen Q, Forray C, Chang RS, Broten TP, Ransom RW, Chan TB, O'Malley SS, Schorn TW, Rodrigues AD, Kassahun K, Pettibone DJ, Freidinger RO, Gluchowski C. De novo design of a novel oxazolidinone analogue as a potent and selective alpha1A adrenergic receptor antagonist with high oral bioavailability. J Med Chem 2000; 43:2775-8. [PMID: 10956183 DOI: 10.1021/jm000085e] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- B Lagu
- Department of Chemistry, Synaptic Pharmaceutical Corporation, Paramus, New Jersey 07652, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Lagu B, Tian D, Chiu G, Nagarathnam D, Fang J, Shen Q, Forray C, Ransom RW, Chang RS, Vyas KP, Zhang K, Gluchowski C. Synthesis and evaluation of furo[3,4-d]pyrimidinones as selective alpha1a-adrenergic receptor antagonists. Bioorg Med Chem Lett 2000; 10:175-8. [PMID: 10673105 DOI: 10.1016/s0960-894x(99)00653-8] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Furo[3,4-d]pyrimidinones were found to be metabolites of dihydropyrimidinones such as 1a-b that are subtype-selective antagonists of the alpha1a-adrenergic receptor. A versatile synthesis that provides access to furo[3,4-d]pyrimidinones in high yield and in enantiomerically pure forms is described along with structure-activity relationships in the series.
Collapse
Affiliation(s)
- B Lagu
- Department of Chemistry, Synaptic Pharmaceutical Corporation, Paramus, NJ 07652, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Nagarathnam D, Miao SW, Lagu B, Chiu G, Fang J, Murali Dhar TG, Zhang J, Tyagarajan S, Marzabadi MR, Zhang F, Wong WC, Sun W, Tian D, Wetzel JM, Forray C, Chang RS, Broten TP, Ransom RW, Schorn TW, Chen TB, O'Malley S, Kling P, Schneck K, Bendesky R, Harrell CM. Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones. J Med Chem 1999; 42:4764-77. [PMID: 10579840 DOI: 10.1021/jm990200p] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Dihydropyrimidinones such as compound 12 exhibited high binding affinity and subtype selectivity for the cloned human alpha(1a) receptor. Systematic modifications of 12 led to identification of highly potent and subtype-selective compounds such as (+)-30 and (+)-103, with high binding affinity (K(i) = 0.2 nM) for alpha(1a) receptor and greater than 1500-fold selectivity over alpha(1b) and alpha(1d) adrenoceptors. The compounds were found to be functional antagonists in human, rat, and dog prostate tissues. Compound (+)-103 exhibited excellent selectively to inhibit intraurethral pressure (IUP) as compared to lowering diastolic blood pressure (DBP) in mongrel dogs (K(b)(DBP)/K(b)(IUP) = 40) suggesting uroselectivity for alpha(1a)-selective compounds.
Collapse
Affiliation(s)
- D Nagarathnam
- Departments of Chemistry and Pharmacology, Synaptic Pharmaceutical Corporation, Paramus, NJ 07652, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Lagu B, Tian D, Nagarathnam D, Marzabadi MR, Wong WC, Miao SW, Zhang F, Sun W, Chiu G, Fang J, Forray C, Chang RS, Ransom RW, Chen TB, O'Malley S, Zhang K, Vyas KP, Gluchowski C. Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 3. Approaches to eliminate opioid agonist metabolites by using substituted phenylpiperazine side chains. J Med Chem 1999; 42:4794-803. [PMID: 10579842 DOI: 10.1021/jm990202+] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Dihydropyrimidinones, such as 1, represent a novel class of alpha(1a) adrenoceptor antagonists with potential for the treatment of benign prostatic hyperplasia (BPH) (see part 1 of this series). Analysis of the metabolites of 1 revealed that 4-methoxycarbonyl-4-phenylpiperidine is formed as the major metabolite and is an agonist at the mu-opioid receptor. To circumvent any potential liability resulting from the metabolite, we decided to identify alternate templates devoid of agonist activity at the mu-opioid receptor to replace the 4-methoxycarbonyl-4-phenylpiperidine moiety. The present study describes the synthesis and SAR of dihydropyrimidinones linked to substituted 4-phenylpiperazine containing side chains. Compound (+)-38 was identified as a lead compound with a binding and functional profile comparable to that of 1. The putative metabolite 2-carboxamidophenylpiperazine has negligible affinity for the mu-opioid receptor.
Collapse
Affiliation(s)
- B Lagu
- Departments of Chemistry and Pharmacology, Synaptic Pharmaceutical Corporation, Paramus, NJ 07652, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Wong WC, Sun W, Lagu B, Tian D, Marzabadi MR, Zhang F, Nagarathnam D, Miao SW, Wetzel JM, Peng J, Forray C, Chang RS, Chen TB, Ransom R, O'Malley S, Broten TP, Kling P, Vyas KP, Zhang K, Gluchowski C. Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 4. Structure-activity relationship in the dihydropyrimidine series. J Med Chem 1999; 42:4804-13. [PMID: 10579843 DOI: 10.1021/jm9902032] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We have previously disclosed dihydropyridines such as 1a,b as selective alpha(1a) antagonists as a potential treatment for benign prostatic hyperplasia (BPH). The propensity of dihydropyridines toward an oxidation led us to find suitable replacements of the core unit. The accompanying papers describe the structure-activity relationship (SAR) of dihydropyrimidinones 2a,b as selective alpha(1a) antagonists. We report herein the SAR of dihydropyrimidines such as 4 and highlight the similarities and differences between the dihydropyrimidine and dihydropyrimidinone series of compounds.
Collapse
Affiliation(s)
- W C Wong
- Departments of Chemistry and Pharmacology, Synaptic Pharmaceutical Corporation, Paramus, NJ 07652, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Murali Dhar TG, Nagarathnam D, Marzabadi MR, Lagu B, Wong WC, Chiu G, Tyagarajan S, Miao SW, Zhang F, Sun W, Tian D, Shen Q, Zhang J, Wetzel JM, Forray C, Chang RS, Broten TP, Schorn TW, Chen TB, O'Malley S, Ransom R, Schneck K, Bendesky R, Harrell CM, Vyas KP. Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 2. Approaches to eliminate opioid agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moiety. J Med Chem 1999; 42:4778-93. [PMID: 10579841 DOI: 10.1021/jm990201h] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We have previously described compound 1a as a high-affinity subtype selective alpha(1a) antagonist. In vitro and in vivo evaluation of compound 1a showed its major metabolite to be a mu-opioid agonist, 4-methoxycarbonyl-4-phenylpiperidine (3). Several dihydropyrimidinone analogues were synthesized with the goal of either minimizing the formation of 3 by modification of the linker or finding alternative piperidine moieties which when cleaved as a consequence of metabolism would not give rise to mu-opioid activity. Modification of the linker gave several compounds with good alpha(1a) binding affinity (K(i) = < 1 nM) and selectivity (>300-fold over alpha(1b) and alpha(1d)). In vitro analysis in the microsomal assay revealed these modifications did not significantly affect N-dealkylation and the formation of the piperidine 3. The second approach, however, yielded several piperidine replacements for 3, which did not show significant mu-opioid activity. Several of these compounds maintained good affinity at the alpha(1a) adrenoceptor and selectivity over alpha(1b) and alpha(1d). For example, the piperidine fragments of (+)-73 and (+)-83, viz. 4-cyano-4-phenylpiperidine and 4-methyl-4-phenylpiperidine, were essentially inactive at the mu-opioid receptor (IC(50) > 30 microM vs 3 microM for 3). Compounds (+)-73 and (+)-83 were subjected to detailed in vitro and in vivo characterization. Both these compounds, in addition to their excellent selectivity (>880-fold) over alpha(1b) and alpha(1d), also showed good selectivity over several other recombinant human G-protein coupled receptors. Compounds (+)-73 and (+)-83 showed good functional potency in isolated human prostate tissues, with K(b)s comparable to their in vitro alpha(1a) binding data. In addition, compound (+)-73 also exhibited good uroselectivity (DBP K(b)/IUP K(b) > 20-fold) in the in vivo experiments in dogs, similar to 1a.
Collapse
Affiliation(s)
- T G Murali Dhar
- Departments of Chemistry and Pharmacology, Synaptic Pharmaceutical Corporation, Paramus, NJ 07652, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Pushkareva M, Chao R, Bielawska A, Merrill AH, Crane HM, Lagu B, Liotta D, Hannun YA. Stereoselectivity of induction of the retinoblastoma gene product (pRb) dephosphorylation by D-erythro-sphingosine supports a role for pRb in growth suppression by sphingosine. Biochemistry 1995; 34:1885-92. [PMID: 7849048 DOI: 10.1021/bi00006a009] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Sphingosine has been shown to inhibit cell growth in many cell lines although the mechanism of this effect remains obscure. More recently, D-erythro-sphingosine has been shown to act as an early inducer of dephosphorylation of the retinoblastoma gene product (pRb) in the lymphoblastic leukemia cell line MOLT-4 [Chao, R., Khan, W., & Hannun, Y.A. (1992) J. Biol. Chem., 267, 23459-23462]. In the current study, the role of the natural D-erythro-sphingosine in regulation of cell growth and pRb dephosphorylation was evaluated using chemically synthesized pure isomers of sphingosine. Of the four possible stereoisomers of sphingosine, D-erythro-sphingosine was most active in inducing dephosphorylation of pRb protein with an EC50% of 0.6 microM whereas its enantiomer L-erythro-sphingosine was 8-fold less potent with an EC50% of 5 microM. The dose responses for inhibition of cell growth were nearly identical to the EC50% for pRb dephosphorylation with D-erythro-sphingosine causing 50% inhibition at 0.6 microM whereas L-erythro-sphingosine was 5-6-fold less potent. All of the stereoisomers were taken up by the cells, and the greater potency of D-erythro-sphingosine was not due to differences in cellular uptake. The metabolism of D-erythro-sphingosine was also studied to evaluate the possible role of sphingosine metabolites on regulation of retinoblastoma protein. Evidence is provided against a role for ceramide or sphingosine 1-phosphate as mediators of the effects of sphingosine on pRb dephosphorylation.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- M Pushkareva
- Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Karl Dieter R, Lagu B, Deo N, Dieter JW. Asymmetric conjugate addition reactions with Chiral Amidocuprates: The effect of Cu(I) salts and coordinating heteroatoms. Tetrahedron Lett 1990. [DOI: 10.1016/s0040-4039(00)97554-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
|